hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

In this letter to the editor, the authors discuss the use of human equilibrative nucleoside transporter 1 (hENT-1) as a biomarker in patients with cholangiocarcinoma. They encourage standardization of techniques to evaluation expression of proteins such as hENT-1 and suggest additional studies inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, Laura L., Puik, Jisce R., Peters, Godefridus J., Kazemier, Geert, Giovannetti, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153344/
https://www.ncbi.nlm.nih.gov/pubmed/27807304
http://dx.doi.org/10.1634/theoncologist.2016-0262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153344/
https://www.ncbi.nlm.nih.gov/pubmed/27807304
http://dx.doi.org/10.1634/theoncologist.2016-0262

Ejemplares similares